Aligos Therapeutics, Inc.

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal - Stocktwits

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal Stocktwits

Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook - TipRanks

Analyst Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target Amid Strengthened HBV Trial Outlook TipRanks

Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment

Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection

ALGS stock rallies 16% after-hours on $25M cash boost from China hepatitis B drug deal - MSN

ALGS stock rallies 16% after-hours on $25M cash boost from China hepatitis B drug deal MSN

H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy - Investing.com

H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy Investing.com